The Unique Role of Fluorodeoxyglucose-PET in Radioembolization

Remco Bastiaannet; Martin A. Lodge; Hugo W.A.M. de Jong; Marnix G.E.H. Lam

doi:10.1016/j.cpet.2019.06.002

The Unique Role of Fluorodeoxyglucose-PET in Radioembolization

Remco Bastiaannet
, Martin A. Lodge
, Hugo W.A.M. de Jong
, Marnix G.E.H. Lam^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.

Original language	English
Pages (from-to)	447-457
Number of pages	11
Journal	PET Clinics
Volume	14
Issue number	4
DOIs	https://doi.org/10.1016/j.cpet.2019.06.002
Publication status	Published - 1 Oct 2019

Keywords

Dose–response
FDG-PET
Metabolic response assessment
Radioembolization

Access to Document

10.1016/j.cpet.2019.06.002

bastiaannetFinal published version, 967 KBLicence: Taverne

Cite this

@article{8d4aee3c24214ab1baa79b37b757036c,

title = "The Unique Role of Fluorodeoxyglucose-PET in Radioembolization",

abstract = "Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.",

keywords = "Dose–response, FDG-PET, Metabolic response assessment, Radioembolization",

author = "Remco Bastiaannet and Lodge, \{Martin A.\} and \{de Jong\}, \{Hugo W.A.M.\} and Lam, \{Marnix G.E.H.\}",

note = "Funding Information: Disclosure: This work has been partially supported by the ENEN + project that has received funding from the Euratom research and training work programme \#755576 (R. Bastiaannet) and Siemens Medical Solutions (H.W.A.M. de Jong). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no [646734]) (H.W.A.M. de Jong). Disclosure: This work has been partially supported by the ENEN + project that has received funding from the Euratom research and training work programme \#755576 (R. Bastiaannet) and Siemens Medical Solutions (H.W.A.M. de Jong). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no [ 646734]) (H.W.A.M. de Jong). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

day = "1",

doi = "10.1016/j.cpet.2019.06.002",

language = "English",

volume = "14",

pages = "447--457",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - The Unique Role of Fluorodeoxyglucose-PET in Radioembolization

AU - Bastiaannet, Remco

AU - Lodge, Martin A.

AU - de Jong, Hugo W.A.M.

AU - Lam, Marnix G.E.H.

N1 - Funding Information: Disclosure: This work has been partially supported by the ENEN + project that has received funding from the Euratom research and training work programme #755576 (R. Bastiaannet) and Siemens Medical Solutions (H.W.A.M. de Jong). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no [646734]) (H.W.A.M. de Jong). Disclosure: This work has been partially supported by the ENEN + project that has received funding from the Euratom research and training work programme #755576 (R. Bastiaannet) and Siemens Medical Solutions (H.W.A.M. de Jong). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no [ 646734]) (H.W.A.M. de Jong). Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.

AB - Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.

KW - Dose–response

KW - FDG-PET

KW - Metabolic response assessment

KW - Radioembolization

UR - https://www.scopus.com/pages/publications/85069930531

U2 - 10.1016/j.cpet.2019.06.002

DO - 10.1016/j.cpet.2019.06.002

M3 - Article

C2 - 31472742

AN - SCOPUS:85069930531

SN - 1556-8598

VL - 14

SP - 447

EP - 457

JO - PET Clinics

JF - PET Clinics

IS - 4

ER -

The Unique Role of Fluorodeoxyglucose-PET in Radioembolization

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this